or
forgot password
  • cancer clinical trials in stamford, CT

  • A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Hematology Oncology, PC
    Stamford, Connecticut 06902
    Lung Cancer, Non-small-cell Lung Carcinoma
    Study of ABI-007 in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
    Hematology/Oncology P.C. Carl & Dorothy Bennet Cancer Center
    Stamford, Connecticut 06902
    Breast Cancer
    Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stamford, Connecticut 06902
    Non Small Cell Lung Cancer
    A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Hematology Oncology, P.C.
    Stamford, Connecticut 06902
    Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
    Non-small Cell Lung Cancer Registry
    Hematology Oncology PC
    Stamford, Connecticut 06902
    Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
    Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
    Carl and Dorothy Bennett Cancer Center at Stamford Hospital
    Stamford, Connecticut 06904
    Breast Cancer
    Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
    Hematology Oncology PC
    Stamford, Connecticut 06902
    Non-Hodgkin's Lymphoma
    A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stamford, Connecticut 06902
    Non-Small Cell Lung Cancer
    OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
    Hematology Oncology, PC (Carl and Dorothy Bennett Cancer Center)
    Stamford, Connecticut 06902
    Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
    Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
    Stamford Therapeutics Consortium
    Stamford, Connecticut 06905
    Atrial Fibrillation, Atrial Flutter
    A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stamford, Connecticut 06902
    Hepatocellular Carcinoma
    Phase 2 Trial of Enzastaurin in Prostate Cancer in Patients Who Have Had Hormonal and Chemotherapy
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stamford, Connecticut 06902
    Prostate Cancer
    An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stamford, Connecticut 06902
    Lung Neoplasms
    Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
    Hematology Oncology, P.C.
    Stamford, Connecticut 06902
    Melanoma
    Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
    Sanofi-Aventis Investigational Site Number 840071
    Stamford, Connecticut 06902
    Colorectal Neoplasms, Neoplasm Metastasis
    Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stamford, Connecticut 06902
    Metastatic Breast Cancer, Locally Advanced Breast Cancer
    Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
    Sanofi-Aventis Investigational Site Number 840032
    Stamford, Connecticut 06902
    Urinary Bladder Neoplasms
    A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
    Hematology Oncology, P.C.
    Stamford, Connecticut 06902
    Non Small Cell Lung Cancer
    A Study for Patients With Small-Cell Lung Cancer
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Stamford, Connecticut 06902
    Small Cell Lung Cancer
    Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
    Hematology Oncology Associates, PC
    Stamford, Connecticut 06902
    Anemia, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small-Cell Lung, Bladder Cancer, Cancer of Head and Neck, Uterine Cervical Cancer